Balaxi Pharmaceuticals Announces Quarterly and Annual Financial Results; Receives Manufacturing License
Balaxi Pharmaceuticals Limited held its Board of Directors meeting on May 28, 2026, and approved the Standalone and Consolidated Audited Financial Results for the fourth quarter and financial year ended March 31, 2026.The Board meeting also included approvals regarding the re-appointment of the company's internal auditors and the recommendation for an independent director's reappointment.
Operational Expansion and Plant Licensing
During the board meeting, the company received the Manufacturing Licence for its pharmaceutical formulation facility in Jadcherla, Hyderabad, on May 23, 2026. This development followed a joint inspection by CDSCO and the successful completion of a CAPA verification audit conducted on April 27, 2026.The Board noted that the company is fully prepared for the commercialization of Paracetamol Tablet 500mg and Piroxicam Capsule 20mg, with required raw and key input materials already received at the facility. Furthermore, Balaxi Pharmaceuticals has initiated the process to obtain manufacturing product permissions for 40 additional products, supporting the phased expansion of its commercial product portfolio.
The company is also progressing towards WHO-GMP certification for the facility and is in the process of submitting the application to the concerned authorities.
Key Financial Results
The company released comprehensive financial data for the quarter and full year ended March 31, 2026.Standalone Financial Results (Rs. in lakhs)
| Particulars | Quarter Ended 31.03.2026 (Audited) | Quarter Ended 31.12.25 (Unaudited) | Quarter Ended 31.03.25 (Audited) | Full Year Ended 31.03.26 (Audited) | Full Year Ended 31.03.25 (Audited) |
|---|---|---|---|---|---|
| Total Income | 2,360.65 | 2,621.74 | 996.98 | 9,051.83 | 6,636.16 |
| Total Expenses | 2,319.29 | 2,409.83 | 1,110.73 | 8,348.57 | 6,107.39 |
| Net Profit/(loss) for the period | 15.81 | 153.06 | (117.85) | 514.69 | 360.13 |
| Basic Earnings Per Share (EPS) | 0.03 | 0.28 | (0.21) | 0.93 | 0.65 |
Consolidated Financial Results (Rs. in Lakhs)
| Particulars | Qtr Ended 31.03.26 | Qtr Ended 31.12.25 | Qtr Ended 31.03.25 | Full Year Ended 31.03.26 | Full Year Ended 31.03.25 |
|---|---|---|---|---|---|
| Total Income | 7,363.10 | 7,263.80 | 7,457.27 | 27,299.47 | 28,884.48 |
| Total Expenses | 7,222.84 | 7,102.82 | 6,491.01 | 26,017.51 | 26,017.51 |
| Net Profit/(loss) for the period | 61.28 | 30.50 | 863.75 | 141.69 | 2,507.02 |
| Basic Earnings Per Share (EPS) | 0.11 | 0.06 | 1.56 | 0.26 | 4.54 |
Balance Sheet Comparison (Rs. in Lakhs)
The Balance Sheet data provides a comparison of the company's assets and liabilities at the end of the financial year.
| Particulars | 31.03.2026 (Audited) | 31.03.2025 (Audited) |
|---|---|---|
| Total Assets | 19,217.12 | 17,444.54 |
| Total Equity | 13,299.99 | 12,785.27 |
| Total Liabilities | 5,917.13 | 4,659.27 |
Governance Updates
The Board of Directors approved the re-appointment of M/s Siva Rama Krishna & Associates, Chartered Accountants (Firm registration number: 013342S), as Internal Auditors of the Company for the financial year 2026-27.Furthermore, the Board recommended the re-appointment of Ms. Akshita Ostwal (DIN: 10026552) as an Independent Director for a second term of five consecutive years. This reappointment is scheduled to commence on September 05, 2026, and the Members' approval will be sought at the ensuing 83rd Annual General Meeting (AGM).
Upcoming General Meeting
The Board of Directors has also approved the notice for the 83rd Annual General Meeting (AGM) of the Company, which is scheduled to be held on Monday, August 24, 2026, via Video Conference/Other Audio Visual Means (VC/OAVM).The company commenced its operations with a focus on its core pharmaceutical segments and continues its expansion plans, targeting both increased production capacity and a broader product portfolio.
BALAXI Stock Price Movement
Shares of BALAXI PHARMACEUTICALS LIMITED slipped by 1.50% on Wednesday, closing at ₹24.97. The stock saw 63,104 shares traded, and settled within a daily range of ₹24.11 to ₹25.9.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: